A Multicenter, Open-label, Single-dose, Systemic Gene Transfer Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9003 on Subjects With Limb Girdle Muscular Dystrophy, Type 2E/R4 (β-Sarcoglycan Deficiency)
Latest Information Update: 26 Sep 2023
At a glance
- Drugs Bidridistrogene xeboparvovec (Primary)
- Indications Limb girdle muscular dystrophy type 2A
- Focus Adverse reactions; Therapeutic Use
- Acronyms VOYAGENE
- Sponsors Sarepta Therapeutics
Most Recent Events
- 18 Sep 2023 Planned End Date changed from 31 Jan 2027 to 28 Aug 2028.
- 18 Sep 2023 Planned primary completion date changed from 31 Jan 2026 to 28 Aug 2028.
- 18 Sep 2023 Status changed from recruiting to active, no longer recruiting.